TY  - JOUR
AU  - López Millán, Belén
AU  - Anguita Mandly, Eduardo Luis
AU  - Menéndez, Pablo
PY  - 2018
DO  - 10.1080/2162402x.2018.1477460
SN  - 2162-402X
UR  - https://hdl.handle.net/20.500.14352/95486
T2  - Oncoimmunology
AB  - Treatment for acute myeloid leukemia (AML) remains suboptimal and many patients remain refractory or relapse upon standard chemotherapy based on nucleoside analogs plus anthracyclines. The crosstalk between AML cells and the BM stroma is a major...
LA  - eng
M2  - e1477460
PB  - Taylor and Francis Group
KW  - Leucemia mieloide aguda
KW  - Modelos murinos
KW  - Tratamiento
TI  - IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML
TY  - journal article
VL  - 7
ER  -